Drug Discovery & Pharmaceuticals

RSS

Single infusion of engineered T-cells achieves lasting asthma remission in mice

Researchers demostrate that durable asthma remission can be achieved with engineered and long-lived CAR T-cell treatment in mice.

31 May 2024

Novel method creates antibody-peptide inhibitor conjugates with enhanced therapeutic efficacy

Tumor cells often hijack normal physiological processes to support their growth, exploiting proteins that are in charge of essential cell functions.

29 May 2024

Novel light-sensitive drug induces sleep without genetic modification

The nucleus accumbens plays a pivotal role in motivational behavior and sleep regulation, modulated by adenosine A2A receptors (A2AR).

28 May 2024

New small molecule offers hope in combating antibiotic resistance

Researchers from the University of Oxford have developed a new small molecule that can suppress the evolution of antibiotic resistance in bacteria and make resistant bacteria more susceptible to antibiotics.

24 May 2024

Insilico Medicine's leadership to address key challenges in AI drug discovery at BIO Convention

Leadership from clinical stage artificial intelligence (AI)-powered drug discovery company Insilico Medicine ("Insilico") will attend the BIO International Convention in San Diego June 3-6 and present on key issues facing AI drug discovery.

23 May 2024

Lemon verbena extract boosts sleep quality

Researchers explore the utility of lemon verbena in improving the sleep of individuals with poor sleep.

22 May 2024

PhoreMost introduces GlueSEEKER platform for discovery of molecular glue degraders

PhoreMost Ltd., a leading UK biopharmaceutical company unlocking the next generation of drug targets, today announced the introduction of GlueSEEKER™.

From PhoreMost 22 May 2024

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS’ CRISPR/Cas9 patent portfolio.

From ERS Genomics 21 May 2024

Insilico and NVIDIA unveil new LLM transformer for solving biological and chemical tasks

In a new paper, researchers from clinical stage artificial intelligence (AI)-driven drug discovery company Insilico Medicine ("Insilico"), in collaboration with NVIDIA, present a new large language model (LLM) transformer for solving biological and chemical tasks called nach0.

20 May 2024

AlphaFold2 can be an effective tool in structure-based drug discovery

One of the most consequential advances in artificial intelligence isn't an eerily conversational chatbot-;it's a new way to unpack the unique 3D structures of proteins.

17 May 2024

Reviving a rejected drug: New selective antibiotic shows promise

Twenty years ago, a drug candidate was rejected due to its side effects. Researchers have now figured out how to potentially make a successor molecule more selective.

17 May 2024

Researchers develop pathoblockers to combat bacterial pneumonia toxins

In most cases, antibiotics are a reliable form of protection against bacterial infections. They have saved billions of human lives since their introduction.

16 May 2024

New therapy shows greater weight loss in mice by targeting brain's appetite center

A groundbreaking paper in Nature describes a promising new therapy for obesity that leads to greater weight loss in mice than existing medications.

16 May 2024

Optibrium partners with FMC Corporation to transform agrochemical discovery

Optibrium, a leading developer of software and AI solutions for drug discovery, has signed a license agreement for its AI-powered discovery platform, Cerella™, with FMC Corporation (FMC), a global leader in crop protection.

From Optibrium Ltd. 15 May 2024

ArgusEye closes €2.8 million funding to accelerate bioprocessing

ArgusEye, a provider of innovative sensor solutions for real-time monitoring of biological systems, today announced the close of its funding, raising €2.8 million EUR (~£2.4 million GBP) bringing the total raised by the Company to €3.45 million EUR (~£3 million GPB).

From ArgusEye AB 13 May 2024

First-in-class drug could prevent sepsis-related organ failure and death

A new drug could prevent sepsis-related organ failure and death by restoring the health of a patient's blood vessels.

8 May 2024

New family of compounds shows promise as treatment for parasitic worms

An international team led by researchers at the University of Toronto has found a family of natural compounds with potential as new and more effective treatments for parasitic worms.

8 May 2024

New Quartet nanocage vaccine shows promise against coronavirus variants

Researchers have developed a novel vaccination approach using Quartet nanocages that display receptor-binding domains (RBDs) from different sarbecoviruses, showing enhanced immune responses and potential protection against diverse coronavirus strains including SARS-CoV-2 and its variants.

8 May 2024

UC San Diego's open source AI platform revolutionizes multi-target drug discovery

Scientists at UC San Diego have developed a machine learning algorithm to simulate the time-consuming chemistry involved in the earliest phases of drug discovery, which could significantly streamline the process and open doors for never-before-seen treatments.

6 May 2024

Genomics plc and GSK collaborate to harness polygenic risk scores in clinical trials

Genomics plc and GSK announced a new collaboration to explore the potential for using polygenic risk scores (PRS) in clinical trials, to improve understanding of disease risk and patient selection, which could support optimization of trial design.

6 May 2024